Prevention of overweight and obesity from a public health perspective

Abstract

International organizations have raised awareness of the increasing prevalence of overweight and obesity worldwide and the impact on morbidity, mortality, quality of life, and cost of healthcare. The development and implementation of obesity prevention strategies requires the identification and understanding of determinant factors that can be influenced by effective large-scale action plans over time. Strategies aimed at the primary prevention of obesity in a population should be multifaceted and designed to actively involve stakeholders and other major parties concerned; in addition, multiple settings for implementation should be considered. In this paper, an overview is presented of the strategies currently in place for obesity prevention, particularly in Spain.

Correlation between Body Mass Index and Fasting Blood Glucose Level in a Selected Group of Teenagers in Bangladesh

“…The trend of increasing overweight and obesity cannot be attributed to the genetic factors only; rather majority of this burden is attributable to the environmental factors, the "Obesogenic environment" 2 . This implies a massive chronic disease burden, resulting in an economic burden in the next 10 to 20 years if nothing is done to prevent it.…”

Physicochemical characteristics of mixed colloidal dispersions: Models for foods containing fat and starch

“…As a result, there has been an increased demand for healthier food products, particularly those with reduced fat, carbohydrate and/or calories (Aranceta, Moreno, Moya, & Anadon, 2009;Grunert, 2006;Hoefkens, Verbeke, & Van Camp, 2011). One of the major challenges in formulating reduced-fat products is maintaining their desirable sensory and physicochemical properties once some or all of the fat is removed (Malone, Appelqvist, & Norton, 2003).…”

Acute cannabinoid receptor type 1 (CB1R) modulation influences insulin sensitivity by an effect outside the central nervous system in mice

“…The prevalence of obesity with its adverse effects on health threatens to undermine recent gains in the prevention of atherosclerotic cardiovascular disease, type 2 diabetes and hypertension [1]. Antagonism of the cannabinoid receptor type 1 (CB1R) of the endocannabinoid system represents a novel pharmacological treatment for obesity and the metabolic syndrome.…”